Nevertheless, the precise mechanisms underlying OM-MOG-mediated immune modulation are not fully defined, and the antigenic heterogeneity of MS and the limited predictive value of EAE models highlight the need for cautious interpretation of preclinical findings. The gene discussed is MOG; the disease is myeloid sarcoma.